bioRxiv Science⌕ Search

Biology subjects

So, E. Y.

Publications and source records attributed to So, E. Y..

2 recordsLinked to original sources

Myeloid Specific Ablation of SHIP1 Boosts ex vivo Expansion and Regulatory Function of Myeloid-Derived Suppressor Cells in Inflammatory Arthritis

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous cell population and the immunosuppressive function of MDSCs has been well established in tumor microenvironment. Recent studies show that adoptive transfer of MDSCs can ameliorate collagen-induced inflammatory arthritis (CIA), a mouse model of human rheumatoid arthritis (RA). Src homology 2 domain- containing inositol polyphosphate 5-phosphatase 1 (SHIP1) was previously shown to regulate MDSC differentiation. In this study, we aimed to generate immunosuppressive MDSCs from mouse bone marrow (BM) through genetic modification combined with cytokine treatments, and to investigate the ability of these ex vivo induced BM-MDSCs to suppress inflammatory responses in the CIA mouse model of RA. We found that myeloid specific ablation of SHIP1 increased the ratio of MDSCs and enhanced their regulatory functions in cytokine induced BM culture. MDSCs from LysMcre:SHIP1flox/flox mouse BM culture demonstrated stronger inhibitory effect on T cell proliferation than those from control mouse BM. Ex vivo induced MDSCs from either control mice or mice with myeloid specific ablation of SHIP1 were administered to the CIA mice as a cell-based therapy to treat inflammatory arthritis. Adoptive transfer of either BM-MDSCs significantly reduced disease incidence and severity, but SHIP1 deficient BM-MDSCs exhibited even higher efficacy compared to wild-type BM-MDSCs. Furthermore, pharmacological inhibition of SHIP1 enhanced the expression of immune regulatory genes in BM-derived MDSCs, and adoptive transfer of these cells protected against CIA development. In conclusion, myeloid specific ablation of SHIP1 boosts ex vivo expansion and immune regulatory function of MDSCs in experimental inflammatory arthritis. These ex vivo generated BM-MDSCs may provide novel therapeutic opportunities for the treatment of RA and other inflammatory diseases.

immunology↗

Enabling CAR-T Cell Immunotherapy in Glioblastoma by Modifying Tumor Microenvironment via Oncolytic Adenovirus Encoding Bispecific T Cell Engager

Recent clinical trials show that CAR-T cell therapies can initially blunt tumor growth in glioblastoma (GBM) patients. However, the tumor microenvironment activates mechanisms that inhibit tumor-killing potential of the CAR-T cells and limit their therapeutic efficacy. To counteract this, we have utilized oncolytic adenovirus (OV) Ad5-{Delta}24-RGD as a platform to overexpress a bispecific T cell engager (BiTE) targeting both T cell marker CD3 and GBM specific tumor associated antigen IL-13R2. We first demonstrated that OV-BiTE could enhance recruitment of T cells to GBM in vitro and in vivo. We then showed that intratumoral injection of OV-BiTE followed by infusion of combined EGFR- and EGFRvIII-CAR-T cells was more effective than OV-BiTE supplemented with either CAR-T therapy alone, and led to significant tumor eradication in a GBM xenograft mouse model. In conclusion, our multimodal OV-BiTE & CAR-T cell immunotherapy is capable of overcoming immunosuppressive tumor microenvironment and GBM resistance to treatment. GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=160 SRC="FIGDIR/small/667708v1_ufig1.gif" ALT="Figure 1"> View larger version (47K): org.highwire.dtl.DTLVardef@c55b15org.highwire.dtl.DTLVardef@deffb2org.highwire.dtl.DTLVardef@64ff90org.highwire.dtl.DTLVardef@c65fc2_HPS_FORMAT_FIGEXP M_FIG C_FIG HIGHLIGHTSO_LIOncolytic adenovirus encoding bispecific T cell engager (OV-BiTE) combines two immunotherapeutic agents into one. C_LIO_LIOV-BiTE strategy modifies tumor microenvironment and enhances recruitment of T cells to glioblastoma (GBM) in vitro and in vivo. C_LIO_LIMultimodal OV-BiTE & CAR-T cell immunotherapy effectively reduced tumor mass in a GBM xenograft mouse model and is superior to either immunotherapy alone. C_LI

cancer biology↗